Chemours (NYSE:CC) Issues Earnings Results, Misses Estimates By $0.05 EPS

Chemours (NYSE:CC) posted its quarterly earnings data on Monday. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05), FiscalAI reports. Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The company had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter last year, the business earned $0.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis.

Chemours Price Performance

NYSE:CC opened at $12.72 on Friday. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. The business’s 50-day simple moving average is $13.96 and its two-hundred day simple moving average is $18.22. The stock has a market cap of $1.91 billion, a PE ratio of -12.47 and a beta of 1.47.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.8%. Chemours’s payout ratio is presently -34.31%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CC shares. Mizuho lowered Chemours from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $15.00 in a research note on Wednesday, October 14th. Zacks Research cut shares of Chemours from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a research report on Tuesday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Chemours in a research report on Tuesday. Finally, BMO Capital Markets reduced their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.45.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions aimed at managing heat in AI data centers, with the company touting improved efficiency and lower water use. The product could help it benefit from growing data-center demand. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Barclays maintained its Hold rating. Other analyst views are mixed, while UBS lowered its price target to $15 and kept a Neutral rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Zacks Research downgraded CC from Hold to Strong Sell, adding to concerns about analyst sentiment. Zacks Research rating information
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers, covering purchases from February 20 through August 4, 2026. The suit alleges securities-law violations, including claims related to 2026 EBITDA guidance and refrigerant sales pulled forward by customer prebuying; these allegations have not been proven. Investors have until December 7 to seek lead-plaintiff status. The repeated alerts concern the same case, rather than separate lawsuits. Article: Lawsuit deadline and allegations regarding 2026 EBITDA guidance

Insider Activity

In other Chemours news, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The stock was purchased at an average price of $15.53 per share, with a total value of $30,050.55. Following the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Denise Dignam purchased 3,378 shares of the stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. The trade was a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.85% of the company’s stock.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.